Skip to main content
YUNGJIN PHARM. CO., LTD logo

YUNGJIN PHARM. CO., LTD — Investor Relations & Filings

Ticker · 003520 ISIN · KR7003520004 KO Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2021-03-03 Proxy Solicitation & In…
Country KR South Korea
Listing KO 003520

About YUNGJIN PHARM. CO., LTD

https://eng.yungjin.co.kr/

Yungjin Pharm. Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products for domestic and international markets. The company's portfolio includes a range of prescription drugs, with a focus on areas such as cephalosporin antibiotics and antipsychotic medications. Yungjin Pharm is actively involved in advancing its R&D pipeline, which includes collaborative research for treatments of rare conditions like mitochondrial diseases. Leveraging extensive drug production expertise and R&D capabilities, the company operates as a key affiliate within the KT&G Group's bio/pharmaceutical business.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains the meeting agenda, proxy solicitation details, and financial statements (balance sheet, income statement, etc.) as required by law for shareholders to make informed voting decisions. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2021-03-03 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for the company 'Youngjin Pharm'. It outlines the meeting date, location, and the specific agenda items (proposals) to be voted on by shareholders, including financial statement approval, board appointments, and remuneration limits. This type of document is a standard proxy solicitation and information statement provided to shareholders prior to a meeting to request their votes.
2021-02-26 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Audit Report / Information Classification · 95% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Youngjin Pharm, a subsidiary of the KT&G corporate group. It provides detailed tables regarding share ownership, inter-company transactions, debt guarantees, and collateral within the corporate group for the quarter. This type of regulatory filing in South Korea, which details corporate structure and inter-company relationships, does not fit into specific categories like 10-K or IR, and is best classified under the fallback category for regulatory announcements. Q1 2024
2021-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Youngjin Pharm) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for preliminary financial results before the final audit report is filed. Since it provides key financial highlights and performance changes rather than a full annual report or a simple announcement of a report's availability, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial performance. FY 2020
2021-02-04 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a formal disclosure by Yungjin Pharm regarding its 'Compliance Program' (CP) and 'Anti-Bribery Management System' (ABMS) status. It details the company's ethical management performance for 2020 and outlines plans for 2021, including ISO 37001 certification maintenance, internal training, and monitoring systems. This type of corporate governance and compliance reporting, which details internal rules and board-level oversight of ethical standards, falls under the Governance Information category.
2021-01-28 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Audit Report / Information Classification · 95% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Youngjin Pharm, a subsidiary of the KT&G corporate group. This is a mandatory regulatory filing in South Korea required by the Fair Trade Commission to report on inter-company shareholdings, financial transactions, debt guarantees, and collateral within a corporate group. Since it is a specific regulatory disclosure document that does not fit into financial reports like 10-K or IR, and is not an announcement of a report, it falls under the 'Regulatory Filings' category. Q1 2024
2020-11-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.